UY40331A - Vacuna contra el coronavirus - Google Patents

Vacuna contra el coronavirus

Info

Publication number
UY40331A
UY40331A UY0001040331A UY40331A UY40331A UY 40331 A UY40331 A UY 40331A UY 0001040331 A UY0001040331 A UY 0001040331A UY 40331 A UY40331 A UY 40331A UY 40331 A UY40331 A UY 40331A
Authority
UY
Uruguay
Prior art keywords
description relates
protein
methods
coronavirus
rna
Prior art date
Application number
UY0001040331A
Other languages
English (en)
Inventor
Alexander Muik
Kayvon Modjarrad
Asaf Poran
Ugur Sahin
Anne SWANSON Kena
Qi Yang
Hui Cai
Original Assignee
Biontech Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US18/071,499 external-priority patent/US12186387B2/en
Application filed by Biontech Se filed Critical Biontech Se
Publication of UY40331A publication Critical patent/UY40331A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta descripción se refiere al campo del ARN para prevenir o tratar la infección por coronavirus. En particular, la presente descripción se refiere a métodos y agentes para la vacunación contra la infección por coronavirus y la inducción de respuestas inmunitarias específicas de antígenos de coronavirus eficaces, como respuestas de anticuerpos y/o células T. Específicamente, en una modalidad, la presente descripción se refiere a métodos que comprenden la administración a un sujeto de ARN que codifica un péptido o proteína que comprende un epítopo de la proteína de espiga del SARS-CoV-2 (proteína S) para inducir una respuesta inmunitaria.
UY0001040331A 2022-06-26 2023-06-26 Vacuna contra el coronavirus UY40331A (es)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202263355648P 2022-06-26 2022-06-26
US202263357628P 2022-06-30 2022-06-30
US202263358522P 2022-07-05 2022-07-05
US202263394571P 2022-08-02 2022-08-02
US202263402444P 2022-08-30 2022-08-30
US202263417680P 2022-10-19 2022-10-19
US202263422404P 2022-11-03 2022-11-03
US202263425290P 2022-11-14 2022-11-14
US18/071,499 US12186387B2 (en) 2021-11-29 2022-11-29 Coronavirus vaccine
US202363486953P 2023-02-24 2023-02-24
US202363452148P 2023-03-14 2023-03-14
US202363465521P 2023-05-10 2023-05-10
US202363469472P 2023-05-29 2023-05-29

Publications (1)

Publication Number Publication Date
UY40331A true UY40331A (es) 2023-12-29

Family

ID=86861772

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001040331A UY40331A (es) 2022-06-26 2023-06-26 Vacuna contra el coronavirus

Country Status (11)

Country Link
EP (1) EP4295862A3 (es)
JP (1) JP2024015475A (es)
KR (1) KR20240002207A (es)
CA (1) CA3204952A1 (es)
DE (1) DE102023002588A1 (es)
FR (1) FR3136962A1 (es)
GB (1) GB2620028B8 (es)
IL (1) IL304032A (es)
NL (1) NL2035173B1 (es)
TW (1) TW202417016A (es)
UY (1) UY40331A (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2024176192A1 (en) * 2023-02-24 2024-08-29 BioNTech SE Immunogenic compositions
WO2025166067A1 (en) * 2024-01-31 2025-08-07 Helix Nanotechnologies, Inc. Sars-cov-2 vaccine compositions and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022009688A (es) * 2020-02-07 2022-12-15 Rnaimmune Inc Composición y métodos de vacunas de arnm contra la nueva infección por coronavirus.
WO2021160346A1 (en) * 2020-02-13 2021-08-19 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
KR20230008801A (ko) * 2020-05-07 2023-01-16 트랜슬레이트 바이오 인코포레이티드 Sars-cov-2 항원을 암호화하는 최적화된 뉴클레오티드 서열
JP2023081859A (ja) * 2021-11-29 2023-06-13 ビオンテック・ソシエタス・エウロパエア コロナウイルスワクチン
EP4469080A2 (en) * 2022-01-28 2024-12-04 BioNTech SE Coronavirus vaccine

Also Published As

Publication number Publication date
EP4295862A2 (en) 2023-12-27
FR3136962A1 (fr) 2023-12-29
NL2035173A (en) 2024-01-08
KR20240002207A (ko) 2024-01-04
GB2620028A (en) 2023-12-27
TW202417016A (zh) 2024-05-01
GB202309598D0 (en) 2023-08-09
CA3204952A1 (en) 2023-12-26
NL2035173B1 (en) 2025-08-29
DE102023002588A1 (de) 2024-01-25
GB2620028B8 (en) 2025-05-28
EP4295862A3 (en) 2024-02-28
JP2024015475A (ja) 2024-02-02
GB2620028B (en) 2025-04-02
IL304032A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
BR112022019781A2 (pt) Vacina para o coronavírus
UY40331A (es) Vacuna contra el coronavirus
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
WO2023147092A3 (en) Coronavirus vaccine
WO2023094713A3 (en) Coronavirus vaccine
AR127585A1 (es) Vacuna de arn de virus sincicial respiratorio
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
MX2022010460A (es) Vacunas contra el coronavirus y metodos de uso.
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
BR112014020019A8 (pt) vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitas a partir destes
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
CO6460752A2 (es) Respuesta inmunitaria reforzada en especies aviares
MX2019003116A (es) Nueva vacuna contra la gripe porcina.
UY40490A (es) Vacunas de combinación para prevenir y/o tratar múltiples agentes infecciosos
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
MX2018003352A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
CO2020009043A2 (es) Anticuerpos humanos contra hemaglutinina de influenza
MX2021004907A (es) Vacuna de ibv 4/91 con proteina espicular heterologa.
MX2016000107A (es) Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria.
BR112023021654A2 (pt) Vacina contra vírus
UY39378A (es) Vacuna de salmonella para el tratamiento de coronavirus
MX2023010703A (es) Composiciones de proteínas de fusión inmunorreguladoras diseñadas por bioingeniería.
AR056733A1 (es) Uso de vacunas para el tratamiento / prevencion de la transmision de patogenos